Bionik Laboratories (BNKL) S-1/A29 May 15IPO registration (amended)Financial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2015
Document Information [Line Items]
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1508381
Entity Filer Category	Smaller Reporting Company
Document Type	S-1
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

Condensed_Consolidated_Interim

Condensed Consolidated Interim Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Current
Cash and cash equivalents	$6,125,108	$209,933	$3,482
Prepaid expenses and other receivables (Note 3)	158,419	81,130	505,787
Due from related parties (Note 6)	41,480	44,986	0
Total Current Assets	6,325,007	336,049	509,269
Equipment (Note 4)	100,629	77,922	6,752
Total Assets	6,425,636	413,971	516,021
Current
Accounts payable (Note 6)	208,785	308,947	120,751
Accrued liabilities	332,946	155,463	128,739
Convertible secured promissory note (Note 5)		0	119,112
Loans payable (Note 6)		0	772,146
Due to related parties (Note 7)		0	149,899
Total Liabilities	541,731	464,410	1,290,647
Shareholders' Equity (Deficiency)
Preferred Stock, par value $0.001; Authorized - 10,000,000; Special Voting Preferred Stock, authorized, issued and outstanding - 1 (December 31, 2014 - Nil)	0	0
Common Stock, Value, Issued	65,840	49,737	1,658,585
Additional paid in capital	12,076,571	4,936,456	114,284
Deficit	-6,300,655	-5,053,982	-2,589,235
Accumulated other comprehensive income	42,149	17,350	41,740
Total Shareholders' Equity (Deficiency)	5,883,905	-50,439	-774,626
Total Liabilities and Shareholders' Equity (Deficiency)	$6,425,636	$413,971	$516,021

Condensed_Consolidated_Interim1

Condensed Consolidated Interim Balance Sheets [Parenthetical] (USD $)	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Preferred Stock, Par Value (in dollars per share)		$0.00
Preferred Stock, Shares Authorized		10,000,000
Preferred Stock, Shares Issued		1
Preferred Stock, Shares Outstanding		1
Common Stock, Par Value (in dollars per share)	$0	$0.00	$0.00
Common Stock, Shares Authorized		150,000,000	200,000,000
Common Stock Authorized	Unlimited
Common Stock, Shares, Issued	11,641,667	15,839,500	0
Common Stock, Shares, Outstanding	11,641,667	50,000,000	49,737,096

Condensed_Consolidated_Interim2

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Expenses
Research and development	$435,671	$232,032	$1,178,837	$747,502	$937,426	$637,661
Professional and consulting fees	261,350	165,302	601,491	407,941	574,875	250,943
General and administrative	167,747	95,699	549,947	205,248	302,353	345,293
Imputed interest expense (Note 5)	0	45,063	27,677	55,647	101,985	7,282
Interest expense	179	17,124	6,212	10,868	28,629	0
Depreciation (Note 4)	10,412	423	34,036	1,349	1,772	2,330
Other income	-323	-473,162	-46,026	0	-495,271	-306,450
Share-based compensation expense (Notes 7(v) and 8)	371,637	0	112,573	0	0	0
Operating Income (Loss)	-1,246,673	-82,481	-2,464,747	-1,428,555	-1,451,769	-937,059
Net loss for the period	-1,246,673	-82,481	-2,464,747	-1,428,555	-1,451,769	-937,059
Foreign exchange translation adjustment for the period	24,779	18,837	-24,390	-553	18,284	23,013
Net loss and comprehensive loss for the period	($1,221,894)	($63,644)	($2,489,137)	($1,429,108)	($1,433,485)	($914,046)
Loss per share - basic and diluted (in dollars per share)	($0.02)	$0	($0.16)	($0.12)	($0.12)	($0.09)
Weighted average number of shares outstanding (in shares)	52,726,746	36,621,885	15,358,291	11,602,879	11,612,900	10,375,937

Condensed_Consolidated_Interim3

Condensed Consolidated Interim Statements of Changes in Shareholders' (Deficiency) Equity (USD $)		Total	Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Mar. 31, 2012		($183,721)		$5	[1]	$16,238	($200,407)	$443
Balance (in shares) at Mar. 31, 2012	[1]			9,000,000
Share issue costs		-34,583		-34,583		0	0	0
Issuance of common shares for cash		1,486,980		1,486,980		0	0	0
Issuance of common shares for cash (in shares)				2,525,000
Issuance of common shares for services		117,192		117,192	[2]	0	0	0
Issuance of common shares for services (in shares)	[2]			200,000
Cancellation of common shares issued to founders		0		0		0	0	0
Cancellation of common shares issued to founders (in shares)				-250,000
Net loss for the period		-937,059		0		0	-937,059	0
Foreign currency translation		23,013		0		0	0	23,013
Balance at Mar. 31, 2013		471,822		1,569,594		16,238	-1,137,466	23,456
Balance (in shares) at Mar. 31, 2013				11,475,000
Share issue costs		-7,329		-7,329		0	0	0
Issuance of common shares for cash		96,320		96,320		0	0	0
Issuance of common shares for cash (in shares)				166,667
Relative fair value of options issued and contributed capital from shareholders		98,046		0		98,046	0	0
Net loss for the period		-1,451,769		0		0	-1,451,769	0
Foreign currency translation		18,284		0		0	0	18,284
Balance at Mar. 31, 2014		-774,626		36,622		1,736,247	-2,589,235	41,740
Balance (in shares) at Mar. 31, 2014				36,621,885
Balance at Dec. 31, 2013		-710,982	0	36,622		1,736,247	-2,506,754	22,903
Balance (in shares) at Dec. 31, 2013			1	36,621,885
Net loss for the period		-82,481	0	0		0	-82,481	0
Foreign currency translation		18,837	0	0		0	0	18,837
Balance at Mar. 31, 2014		-774,626	0	36,622		1,736,247	-2,589,235	41,740
Balance (in shares) at Mar. 31, 2014			1	36,621,885
Share issue costs		-11,609	0	0		-11,609	0	0
Issuance of common shares for cash		2,616,062	0	10,792		2,605,270	0	0
Issuance of common shares for cash (in shares)			0	10,792,335
Shares issues on conversion of loans		239,746	0	1,012		238,734	0	0
Shares issues on conversion of loans (in shares)			0	1,012,142
Beneficial conversion feature		27,677	0	0		27,677	0	0
Shares issued on exercise of stock options		228,875	0	1,311	[3]	227,564	0	0
Shares issued on exercise of stock options (in shares)			0	1,310,734	[3]
Share compensation expense		112,573	0	0		112,573	0	0
Net loss for the period		-2,464,747	0	0		0	-2,464,747	0
Foreign currency translation		-24,390	0	0		0	0	-24,390
Balance at Dec. 31, 2014		-50,439	0	49,737		4,936,456	-5,053,982	17,350
Balance (in shares) at Dec. 31, 2014			1	49,737,096
Effect of the Acquisition Transaction		0	0	6,000		-6,000	0	0
Effect of the Acquisition Transaction (in shares)			0	6,000,000
Shares issued on private placement		7,871,601	0	9,840		7,861,761	0	0
Shares issued on private placement (in shares)			0	9,839,500
Share issue costs		-1,087,020	0	0		-1,087,020	0	0
Share compensation expense		371,637	0	263		371,374	0	0
Share compensation expense (in shares)			0	262,904
Net loss for the period		-1,246,673	0	0		0	-1,246,673	0
Foreign currency translation		24,779	0	0		0	0	24,799
Balance at Mar. 31, 2015		$5,883,905	$0	$65,840		$12,076,571	($6,300,655)	$42,149
Balance (in shares) at Mar. 31, 2015			1	65,839,500

[1]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[2]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[3]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.

Condensed_Consolidated_Interim4

Condensed Consolidated Interim Statements of Cash Flows (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Operating activities
Net loss for the period	($1,246,673)	($82,481)	($2,464,747)	($1,428,555)	($1,451,769)	($937,059)
Adjustment for items not affecting cash
Depreciation of equipment	10,412	423	34,036	1,349	1,772	2,330
Imputed interest	0	45,063	27,677	55,647	101,985	7,282
Interest expense	179	17,124	0	0	19,223	0
Share compensation expense	371,637	0	112,573	0	0	117,192
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	-864,445	-19,871	-2,290,461	-1,371,559	-1,328,789	-810,255
Changes in non-cash working capital items
Prepaid expenses and other receivables	-83,258	-409,680	420,709	393,900	-182,783	-281,604
Accounts payable	-71,773	0	195,427	116,122	41,261	25,195
Accrued liabilities	193,993	-10,113	34,847	70,407	124,221	-11,238
Net cash used in operating activities	-825,483	-439,664	-1,639,478	-791,130	-1,346,090	-1,077,901
Investing activities
Acquisition of equipment	-38,820	0	-109,316	-4,557	0	-8,695
Net cash used in investing activities	-38,820	0	-109,316	-4,557	0	-8,695
Financing activities
Proceeds from issuance of shares, net of issue costs	6,788,988	0	2,604,453	88,991	147,837	1,393,551
(Repayment of) proceeds from loans payable	0	371,718	-733,293	482,050	810,553	0
Proceeds from exercise of options			228,875	0	0	0
(Repayment of) proceeds from loans from related parties	0	-20,295	-111,357	84,107	184,594	-117,946
Net cash provided by financing activities	6,788,988	351,423	1,988,678	655,148	1,142,984	1,275,605
Effects of foreign currency exchange rate changes	-9,510	89,442	-33,433	23,706	-26,652	29,288
Net increase in cash and cash equivalents for the period	5,915,175	1,201	206,451	-116,833	-229,758	218,297
Cash and cash equivalents, beginning of period	209,933	2,281	3,482	233,240	233,240	14,943
Cash and cash equivalents, end of period	6,125,108	3,482	209,933	2,281	3,482	233,240
Supplemental information:
Issuance of shares on conversion of loans	500,000	0	239,746	0	0	0
Interest paid			$0	$0	$9,406	$0

NATURE_OF_OPERATIONS

NATURE OF OPERATIONS	3 Months Ended		9 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1	NATURE OF OPERATIONS		1	NATURE OF OPERATIONS

	The Company and its Operations		The Company and its Operations

	Bionik Laboratories Corp. (formerly Drywave Technologies, Inc., herein referred to as the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved September 24, 2014. The unaudited condensed consolidated financial statements consolidate the Company and its wholly owned subsidiaries Bionik Laboratories Inc. ("Bionik Canada") and Bionik Acquisition Inc.		Bionik Laboratories Inc. (the “Company” or “Bionik”) is a Canadian private company incorporated under the Canada Business Corporation Act on March 24, 2011 and domiciled in Ontario, Canada. The Company’s registered head office is located at 483 Bay Street, N105, Toronto, Ontario, M5G 2C9.

	The Company is a bioengineering research and development company targeting diseases and injuries that impact human mobility. The Company is working towards its first product, which will be the “ARKE”, a robotic pair of exoskeleton legs to be used for rehabilitation purposes and potentially for day-to-day use as a replacement for a wheelchair.		The Company is a bioengineering research and development company targeting diseases and injuries that impact human mobility. The Company is working towards its first market ready product, which will be the “ARKE”, a robotic pair of exoskeleton legs to be used for rehabilitation purposes and potentially for day-to-day use as a replacement for a wheelchair.

	These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business.		These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business.

	On February 26, 2015, the Company finalized a Share Exchange Agreement whereby Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the outstanding common shares of Bionik Canada (the “Acquisition Transaction”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of common stock of the Company. In addition the Company issued one share of its Special Preferred Voting Stock (the “Special Preferred Share”) (Note 7). Immediately prior to the closing of the Acquisition Transaction, Drywave transferred all of the business, properties, assets, operations and liabilities to two former officers and directors of the Company and to a third-party entity such that as of the closing of the Acquisition Transaction there were no assets or liabilities.		The Company has not yet realized any revenues from its planned operations. As December 31, 2014 the Company has a working capital deficit of $128,361 (March 31, 2014 - $781,378) and shareholders’ deficit of $50,439 (March 31, 2014 - $774,626), incurred a net loss and comprehensive loss of $2,489,137 for the period ended December 31, 2014 (December 31, 2013 - $1,429,108; year ended March 31, 2014 - $1,433,485; year ended March 31, 2013 - $914,046). Further, the Company plans to initially categorize the ARKE as a Class I or Class II medical device with the U.S. Food and Drug Administration (“FDA”) and accordingly will be subject to FDA regulations, guidelines and the FDA’s Quality System Regulation (“QSR”) in order to market and sell their product in the U.S. The costs of obtaining the necessary FDA approval and maintaining compliance with the FDA could be significant, see Note 12.

	After giving effect to the Acquisition Transaction, the Company commenced operations through Bionik Canada which by virtue of the Acquisition Transaction is now a reporting issuer through the Company’s listing on the OTC Pink marketplace.

	As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Acquisition Transaction, for accounting purposes the Acquisition Transaction does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Acquisition Transaction.

	References to the Company refer to the Company and its wholly—owned subsidiaries, Bionik Acquisition Inc. and Bionik Laboratories Inc. References to Drywave relate to the Company prior to the Acquisition Transaction.

	The Company has not yet realized any revenues from its planned operations. As at March 31, 2015, the Company has a working capital surplus of $5,783,276 (December 31, 2014 - a working capital deficit of $128,361) and shareholders’ equity of $5,883,905 (December 31, 2014 - a shareholder’s deficiency of $50,439) and incurred a net loss and comprehensive loss of $1,221,984 for the three- month period ended March 31, 2015 (March 31, 2014 - $63,644). Further, the Company expects that the ARKE will be categorized as a Class II medical device with the U.S. Food and Drug Administration (“FDA”) and accordingly will be subject to FDA regulations, guidelines and the FDA’s Quality System Regulation (“QSR”) in order to market and sell their product in the U.S. The costs of obtaining the necessary FDA approval and maintaining compliance with the FDA could be significant. See Note 11.

	The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, M5G 2C9.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended		9 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2	SIGNIFICANT ACCOUNTING POLICIES		2	SIGNIFICANT ACCOUNTING POLICIES

	Unaudited Condensed Consolidated Interim Financial Statements		Use of Estimates

	These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements for the year ended December 31, 2014. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.		The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: investment tax credit receivable (see note 3) and the valuation allowance for deferred tax assets.

	Recently Issued Accounting Pronouncements		Foreign Currency Translation

	On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed interim financial statements of adopting ASU 2014-09 will be assessed by management.		The Company’s functional currency is the Canadian dollar and its reporting currency is the US dollar. The financial statements have been translated into US dollars in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830. All assets and liabilities with Canadian dollars as functional currency are translated at the exchange rate on the balance sheet date, shareholders' equity and share issuances are translated at the historical rates and the statements of operations and cash flows are translated at the average exchange rate for the year. The resulting translation adjustments are reported under comprehensive income as a separate component of shareholders’ equity (deficiency).

	On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the condensed interim financial statements of adopting ASU 2014-15 will be assessed by management.		Equipment

	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements.		Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows:

	Foreign Currency Translation		Computers and electronics	50% per annum
			Furniture and fixtures	20% per annum
	The Company’s reporting currency is the U.S. dollar. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company is the U.S. dollar, the functional currency of the Company’s wholly-owned subsidiary Bionik Canada and Bionik Acquisition Inc. is the Canadian Dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.		Tools and parts	20% per annum

	Bionik Canada and Bionik Acquisition Inc.’s assets and liabilities are translated into the U.S. dollar using the exchange rates at each balance sheet date. Revenue and expenses are translated at average rates prevailing during the reporting period. Shareholders’ equity (deficiency) is translated at historical rates. Adjustments resulting from translating the condensed consolidated interim financial statements into the U.S. dollar are recorded as a separate component of accumulated other comprehensive income (loss) in the statement of changes in shareholders’ equity (deficiency).		Revenue Recognition

			The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured.

			Government Grant and Input Tax Credit Recoveries

			The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statements of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when it is certain that such grant and input tax credit recoveries will be received.

			Cash and Cash Equivalents

			Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.

			Research and Development

			The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.

			Segment Reporting

			ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s does not have any reportable segments. All of its operations and assets are domiciled in Canada.

			Income Taxes

			Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations.

			Fair Value of Financial Instruments

			ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item.

			The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable and accrued liabilities, convertible secured promissory note and due to / from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

			For the loans payable, the Company believes the carrying value of the loans payable approximates fair value as the interest rates are market rates.

			There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014 nor March 31, 2014.

			Derivative Financial Instruments

			The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.

			The Company reviews the terms of convertible loans, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants to employees and non-employees in connection with consulting or other services. These options or warrants may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity.

			Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received an immediate charge to income is recognized in order to initially record the derivative instrument liabilities at their fair value.

			The discount from the face value of the convertible debt or equity instruments resulting from allocating some or all of the proceeds to the derivative instruments, together with the stated rate of interest on the instrument, is amortized over the life of the instrument through periodic charges to income, using the effective interest method.

			The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

		Basic and Diluted Loss Per Share

		Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. The dilutive effect of convertible loans is reflected in diluted weighted average number of shares using the if-converted method, when there is a dilutive effect.

		Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents are excluded from the computation of diluted loss per share when their effect is anti-dilutive.

		Impairment of Long-Lived Assets

		The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.

		Recently Adopted Accounting Pronouncements

		“Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements (“ASU 2014-10”) issued in June 2014, ASU 2014-10 eliminated the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 are effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 for its financial statements and accordingly has removed the inception-to-date information.

		“Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”, (“ASU 2013-2”) issued in February 2013 requires entities to disclose additional information for items reclassified out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities are required to disclose the effect of the reclassification on each affected line item of net income. For AOCI reclassification items that are not reclassified in their entirety into net income, a cross reference to other required U.S. GAAP disclosures is required. This information may be provided either in the notes or parenthetically on the face of the statement that reports net income, provided that all the information is disclosed in a single location. However, an entity is prohibited from providing this information parenthetically on the face of the statement that reports net income, if it has items that are not reclassified in their entirety into net income. The guidance is effective for annual and interim reporting periods beginning after December 15, 2012. The adoption of this standard did not have a material impact on the financial statements of the Company.

		Recently Issued Accounting Pronouncements

		“Income Taxes (Topic - 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists” (“ASU 2013-11”) issued in July 2013 provides guidance on how to present an unrecognized tax benefit. The guidance is effective for annual periods beginning after December 15, 2013.

		On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is not permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-09 is being assessed by management.

		On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-15 is being assessed by management.

		Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

PREPAID_EXPENSES_AND_OTHER_REC

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended				9 Months Ended
PREPAID EXPENSES AND OTHER RECEIVABLES	Mar. 31, 2015				Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	3	PREPAID EXPENSES AND OTHER RECEIVABLES			3	PREPAID EXPENSES AND OTHER RECEIVABLES

			March 31,	December 31,			December 31,	March 31,
			2015	2014			2014	2014
			$	$			$	$
	Prepaid expenses and sundry receivables		6,242	18,172	Prepaid expenses and sundry receivables		18,172	11,700
	Prepaid insurance		126,771	40,630	Prepaid insurance		40,630	-
	Sales taxes receivable (i)		25,406	22,328	IRAP Grant receivable (i)		-	63,300
			158,419	81,130	Investment tax credit receivable (ii)		-	408,506
					Sales taxes receivable (iii)		22,328	22,281
							81,130	505,787
		(i)	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.
						i)	Industrial Research Assistance Program (“IRAP”) grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as ‘Other Income’ in the statements of operations and comprehensive loss, when received.

						ii)	Investment tax credit receivable is the estimated Scientific Research and Experimental Development (“SR&ED”) claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as ‘Other Income’ in the statements of operations and comprehensive loss.

						iii)	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

EQUIPMENT

EQUIPMENT	3 Months Ended								9 Months Ended
EQUIPMENT	Mar. 31, 2015								Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4	EQUIPMENT							4	EQUIPMENT

	Equipment consists of the following as at March 31, 2015 and December 31, 2014.								Equipment consists of the following as at December 31, 2014 and March 31, 2014

			March 31, 2015			December 31, 2014					December 31, 2014			March 31, 2014
			Cost	Accumulated	Net	Cost	Accumulated	Net			Cost	Accumulated	Net	Cost	Accumulated	Net
			Cost	Depreciation	Net	Cost	Depreciation	Net			Cost	Depreciation	Net	Cost	Depreciation	Net
			$	$	$	$	$	$			$	$	$	$	$	$
	Computers and electronics		107,369	33,933	73,436	77,650	27,438	50,212	Computers and electronics		77,650	27,438	50,212	-	-	-
	Furniture and fixtures		23,832	7,689	16,143	24,909	7,325	17,584	Furniture and fixtures		24,909	7,325	17,584	11,194	4,442	6,752
	Tools and parts		12,100	1,050	11,050	11,913	1,787	10,126	Tools and parts		11,913	1,787	10,126	-	-	-
			143,301	42,672	100,629	114,472	36,550	77,922			114,472	36,550	77,922	11,194	4,442	6,752

	Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the period ended March 31, 2015 was $10,412 (March 31, 2014 - $423).								Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the nine month period ended December 31, 2014 was $34,036 (December 31, 2013 - $1,349) and during the year ended March 31, 2014 was $1,772 (March 31, 2013 - $2,330).

									Equipment is translated to U.S. Dollars using the rate of exchange prevailing at the balance sheet date. There were no disposals and $109,316 in additions during the nine month period ended December 31, 2014 (December 31, 2013 - $4,557). The remaining change in cost from March 31, 2014 to December 31, 2014 is due to foreign exchange translation. During the year ended March 31, 2013 there were $8,695 of additions to equipment.

CONVERTIBLE_SECURED_PROMISSORY

CONVERTIBLE SECURED PROMISSORY NOTE	3 Months Ended		9 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	5	CONVERTIBLE SECURED PROMISSORY NOTE	5	CONVERTIBLE SECURED PROMISSORY NOTE

	On December 8, 2011, the Company received $61,500 CAD from a lender that at the time was non-interest bearing and had no specified terms of repayment. On February 28, 2012, the lender and the Company agreed to the terms of a Convertible Secured Promissory Note, which securitized the previous note plus an additional $60,000 CAD for a total principal amount of $121,500 CAD. The note was interest bearing at prime plus 1%, secured by a general security agreement and was to mature on the earlier of a qualifying financing event or February 28, 2014. The lender had an option to convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing event prior to February 28, 2014.		On December 8, 2011, the Company received $61,500 CAD from a lender that at the time was non-interest bearing and had no specified terms of repayment. On February 28, 2012 the lender and the Company agreed to the terms of a Convertible Secured Promissory Note, which securitized the previous note plus an additional $60,000 CAD for a total principal amount of $121,500 CAD. The note bears interest at prime plus 1% and matured on the earlier of a qualifying financing event or February 28, 2014. The “qualifying financing event” is defined as an equity financing (including convertible securities) that is completed on or prior to the maturity date where the Company issues securities for aggregate gross proceeds equal to or greater than $1.5 million CAD. The loan was secured by a general security agreement under which the Company pledged, assigned, charged and granted to the lender a security interest in and to the property, assets and undertaking of the Company.

	The note matured on February 28, 2014, at this point the conversion option expired and the note became due on demand; however, no repayment was demanded. Upon the occurrence of the April financing (Note 7 (i)) the Company agreed to honor the original conversion option and a beneficial conversion feature of $27,677 was recognized. As the note was due on demand the Company immediately recognized imputed interest of $27,677 in the condensed consolidated interim statement of operations and comprehensive loss.		The lender had an option to convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing event prior to February 28, 2014. The Company evaluated the conversion option on inception and determined that it was based on a contingent event and accordingly, the option was not valued.

	On May 9, 2014, the lender converted the note plus accrued interest into common shares based on the 20% discount to the $0.81 ($0.90 CAD) per share equity financing that was accomplished in April 2014 and the Company issued these pre-transaction shares in June 2014. (See Note 7(iii)).		The Company determined that a market interest rate for similar debt would be approximately 10% per annum and accordingly, recognized the note at its present value based on a 10% discount rate, or $105,262, and allocated the discount of $16,238 from the face value of $121,500 to additional paid in capital, which due to achieving parity the USD and CAD amounts were not materially different. The discount of $16,238 was amortized to February 28, 2014 when the note was due to mature. The Company expensed imputed interest of $27,677 and $55,647 during the nine month periods ended December 31, 2014 and 2013, respectively, and $3,939 and $7,282 during the years ended March 31, 2014 and 2013, respectively.

			The note matured on February 28, 2014, at this point the conversion option expired and the note became due on demand; however, no repayment was demanded. Upon the occurrence of the April 2014 financing (Note 8(x)) the Company agreed to honor the original conversion option and a beneficial conversion feature of $27,677 was recognized. As the note was due on demand the Company immediately recognized imputed interest of $27,677 in the statements of operations and comprehensive loss for the nine months ended December 31, 2014.

			On May 9, 2014, the lender converted the note plus accrued interest in to common shares based on the 20% discount to the $0.81 ($0.90 CAD) per share equity financing that was accomplished in April 2014 and the Company issued these shares in June 2014 (see Note 8(xiii)).

LOANS_PAYABLE

LOANS PAYABLE	9 Months Ended
LOANS PAYABLE	Dec. 31, 2014
Debt Disclosure [Abstract]
Loans Payable [Text Block]	6	LOANS PAYABLE

	As of December 31, 2014 and March 31, 2014, the Company has the following loans:

			December 31, 2014	March 31, 2014
			$	$
	a) Lieberman Family Trust
	The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million). Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014.		-	27,141

	b) Gaston-Dreyfus Remi
	The loan carried interest of 6% per annum and was payable on demand. The loan was secured by a general security agreement on all the assets of the Company.		-	454,729

	c) Parvez Patel/Huda
	The loan was unsecured, carried interest of 2% per annum and was repayable on demand or successful completion of capital raise for $5,694,570 (CAD $6.3 million).		-	100,766

	d) Pope & Co.
	The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million) by no later than June 30, 2014. Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014.		-	189,510

			-	772,146

		(a)	During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 common shares (Note 8(xii)).

		(b&c)	During the nine month period ended December 31, 2014, the Company repaid the loan of $452,350 ($500,000 CAD) from Gaston-Dreyfus Remi plus accrued interest and the loan of $99,517 ($110,000 CAD) plus accrued interest from Parvez Patel/Huda (both unrelated parties).

		(d)	During the nine month period ended December 31, 2014, the Company repaid loans for $180,940 ($200,000 CAD) plus accrued interest of $12,138 ($13,417 CAD) owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares of BLC (Note 13(c)) at an exercise price of $0.23 per share for a period of up to two years.

	On June 10, 2013, the Company agreed to the terms of a secured loan for $241,185 ($250,000 CAD) that bore interest at 10%, was secured by a general security agreement, and matured on the earlier of June 10, 2014, two days after receiving the 2013 SR&ED claim or within five days of an event of default. Events of default consisted of standard non-payment clauses.

	Under the terms of the loan agreement the lenders received an aggregate of 100,000 shares from the personal shareholdings of the founders as well as options to purchase 416,666 common shares. The shares contributed personally by the founders were valued based on the price of the most recent private placement in March 2013 at $0.60 CAD, see Note 8, which at the time of the loan was $0.58 for a fair value of $58,000 ($60,000 CAD). As detailed in Note 9, the fair value of the stock options was $106,185. The fair value of these instruments was then utilized to allocate the proceeds based on the relative fair values of the loan, the contributed shares and the options, resulting in a carrying value of $143,139 for the loan, $63,481 for the options and $34,565 for the shares. The values for the shares as contributed capital and the options aggregating to $98,046 were recognized in contributed surplus.

	The loan was repaid on November 15, 2013, and the Company recognized accretion of the full amount of the discount of $98,046 as imputed interest in the statements of operations and comprehensive loss for the year ended March 31, 2014.

RELATED_PARTY_TRANSACTIONS_AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended			9 Months Ended
	Mar. 31, 2015			Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	6	RELATED PARTY TRANSACTIONS AND BALANCES			7	RELATED PARTY TRANSACTIONS AND BALANCES

	Due from related parties			Due from related parties
					(a)	As of December 31, 2014, the Company has advances receivable from the Chief Operating Officer (“COO”) and Chief Technology Officer (“CTO”) for $44,986 (March 31, 2014 – $149,899 payable to). These advances are unsecured, bear interest at a rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and are payable on demand in Canadian dollars. During the period the Company repaid the loans provided as of March 31, 2014; the Company advanced funds to settle a tax assessment; the Company paid additional salary amounts that had not been made during the period; and, the Company reimbursed $37,837 ($44,000 CAD) related to various out-of-pocket costs they incurred on behalf of the Company, all of which resulted in a net advance of $44,986 as at December 31, 2014.
		(a)	As of March 31, 2015, the Company had advances receivable from the Chief Operating Officer (“COO”) and Chief Technology Officer (“CTO”) for $41,480 (December 31, 2014 – $44,986). These advances are unsecured, bear interest at a rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and are payable on demand in Canadian dollars. The Company advanced funds to settle a tax assessment; the Company paid additional salary amounts that had not been made during the period; and the Company reimbursed $37,837 ($44,000 CAD) related to various out-of-pocket costs they incurred on behalf of the Company, all of which resulted in a net advance of $41,480 as of March 31, 2015.
				Issuance of shares to settle due to related party
	Issuance of shares to settle due to related party				(b)	During the nine months ended December 31, 2014, one advance amounting to $85,947 ($95,000 CAD) (2013 - $Nil) was settled by issuance of 105,555 common shares to a former director (Note 8(xi)).

		(b)	During the nine months ended December 31, 2014, one advance amounting to $85,947 ($95,000 CAD) was settled by the issuance of 105,555 pre-Acquisition Transaction common shares of Bionik Canada to a former director.	Accounts payable and accrued liabilities
					(c)	As at December 31, 2014 there is $4,220 (March 31, 2014 - $16,235) owing to the Chief Executive Officer (“CEO”) and $5,930 (March 31, 2014 - $Nil) owing to the CTO, both of which are included in accounts payable.
	Accounts payable and accrued liabilities
					(d)	As at December 31, 2014 there is $Nil (March 31, 2014 - $48,673) owing to a former director included in accrued liabilities.
		(c)	As at March 31, 2015, $1,490 (December 31, 2014 - $4,220) was owing to the CEO, $9,752 (December 31, 2014 - $5,930) was owing to the CTO and $7,025 was owing to the COO, related to business expenses, all of which are included in accounts payable.

SHARE_CAPITAL

SHARE CAPITAL	3 Months Ended
SHARE CAPITAL	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7	SHARE CAPITAL

				March 31, 2015					December 31, 2014
				Number of		$			Number of		$
				shares		$			shares		$
	Exchangeable Shares:
	Balance at beginning of period				49,737,096		49,737			36,621,885		36,622
	Shares issued for services		(v)		262,904		263			-		-
	Shares issued under private placement				-		-	(i)		10,792,335		10,792
	Shares issued on conversion and settlement of debt				-		-	(ii)(iii)		1,012,142		1,012
	Shares issued on the exercise of options				-		-	(iv)		1,310,734		1,311
	Balance at end of the period				50,000,000		50,000			49,737,096		49,737
	Common Shares
	Balance at beginning of the period				-		-			-		-
	Shares issued as Acquisition Transaction consideration		(vii)		6,000,000		6,000			-		-
	Shares issued under private placement		(vi)-(ix)		9,839,500		9,840			-		-
	Balance at end of the period				15,839,500		15,840			-		-
	TOTAL COMMON SHARES				65,839,500		65,840			-		-

		(i)	In April, 2014, Bionik Canada completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,590,160. A former director of Bionik Canada assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction.

		(ii)	In May 2014, Bionik Canada issued 436,908 common shares in exchange for the settlement of $138,888 of unsecured debt.

		(iii)	In June, 2014, Bionik Canada issued 575,234 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement.

		(iv)	In June 2014, Bionik Canada issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875.

		(v)	On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 7(vi)), and recorded in stock based compensation on the statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders the Company intends to reimburse the CTO and COO 320,000 shares of common stock; however, these shares have not yet been issued.

		(vi)	Concurrently with the closing of the Acquisition Transaction on February 26, 2015, the Company issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years.

		(vii)	Immediately following the Acquisition Transaction and the First Closing, 6,000,000 shares of common stock were held by existing Drywave stockholders, 7,735,750 shares of common stock were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of common stock through their ownership of 100% of the Exchangeable Shares which vote alongside the common stock of the Company as a single class through the one issued and outstanding Special Preferred Share.

		(viii)	On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years.

		(ix)	On March 31, 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Third Closing of $97,098 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years.

	Special Voting Preferred Share

	In connection with the Acquisition Transaction (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries.

	In connection with the Acquisition Transaction and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Preferred Share. The Special Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement.

	The Special Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company.


	The voting rights of the Special Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

CAPITAL_STOCK

CAPITAL STOCK	9 Months Ended
CAPITAL STOCK	Dec. 31, 2014
Equity [Abstract]
Capital Stock [Text Block]		8	CAPITAL STOCK

			Number of	Stated
			Common	Value
			Shares	$
	Balance, April 1, 2012 (i)		9,000,000	5
	Issued under private placement (ii)		291,667	170,815
	Issued on settlement of debt relating to prior period services (iii)		200,000	117,192
	Issued under private placement (iv)		895,834	519,420
	Cancellation of common stock (v)		-250,000	-
	Issued under private placement (vi)		437,500	256,016
	Issued under private placement (vii)		383,333	232,546
	Issued under private placement (viii)		516,666	308,183
	Share issue costs		-	-34,583
	Balance, March 31, 2013		11,475,000	1,569,594
	Issued under private placement (ix)		166,667	96,320
	Share issue costs		-	-7,329
	Balance, March 31, 2014		11,641,667	1,658,585
	Issued under private placement (x)		3,430,756	2,616,062
	Issued on conversion and settlement of debt (xi), (xii), (xiii)		321,748	239,746
	Issued on the exercise of options (xiv)		416,667	335,060
	Share issue costs (x)		-	-11,609
	Balance December 31, 2014		15,810,838	4,837,844

		(i)	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2,1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.

		(ii)	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.

		(iii)	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.

		(iv)	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.

		(v)	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.

		(vi)	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.

		(vii)	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.

		(viii)	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.

		(ix)	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.

		(x)	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finder’s fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.

		(xi)	In May 2014, the Company issued 105,555 common shares to a director of the Company in exchange for the settlement of $87,638 ($95,000 CAD) of unsecured debt.

		(xii)	In May 2014, the Company issued 33,333 common shares to the Libermann Family Trust in exchange for the settlement of $27,585 ($30,000 CAD) of unsecured debt.

		(xiii)	In June, 2014, the Company issued 182,860 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 ($131,659 CAD) and was converted at a 20% discount to the $0.68 ($0.90 CAD) April 2014 private placement.

		(xiv)	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.

STOCK_OPTIONS

STOCK OPTIONS	3 Months Ended															9 Months Ended
STOCK OPTIONS	Mar. 31, 2015															Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8	STOCK OPTIONS														9	STOCK OPTIONS

	The purpose of the Company’s stock option plan is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company.															The Company has a stock option plan, the purpose of which is to attract, retain and motivate persons connected to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company.

	Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed fifteen (15%) percent of the issued share capital or such greater number of shares as may be determined by the Board and approved, if required, by the shareholders of the Company and by any applicable stock exchange or other regulatory authority. Optioned shares in respect of which options are not exercised shall be available for subsequent options.															Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed eight (8%) percent of the issued share capital or such greater number of shares as may be determined by the Board and approved, if required, by the shareholders of the Company and by any applicable stock exchange or other regulatory authority. Optioned shares in respect of which options are not exercised shall be available for subsequent options.

	On April 11, 2014 and June 20, 2014 the Company issued 657,430 and 264,230 options to employees and a consultant at an exercise price of $0.165 and $0.23, respectively, with a term of seven years. The options vest one-third on grant date and two thirds equally over the subsequent two years on the anniversary date. During the year ended December 31, 2014, 125,824 of the 657,430 options were cancelled. On February 26, 2015, as a result of the Acquisition Transaction, the options were revalued. The fair value as remeasured of the 531,606 April issuance and the 264,230 June issuance was $230,930 and $118,957 respectively. During the period ended March 31, 2015, $73,860 and $36,684 has been recorded as stock-based compensation related to the vesting of these stock options.															On June 10, 2013, the Company issued 416,667 options to a shareholder. The options vested immediately and have an exercise price of $0.52 ($0.60 CAD) per share and a time to expiration of one year. These options were valued at $106,185. These options were exercised during the year (Note 8(xiv)).

	On July 1, 2014, the Company issued 2,972,592 options to management of the Company, at an exercise price of $0.23 with a term of 7 years, which vest May 27, 2015. On February 26, 2015, as a result of the Acquisition Transaction, the options were re-valued. The fair value of the options was $1,259,487.															On April 11, 2014 and June 20, 2014 the Company issued 209,000 and 84,000 options to employees and a consultant at an exercise price of $0.52 ($0.60 CAD) and $0.77 ($0.90 CAD), respectively, which all vest one-third on grant date and two thirds equally over the subsequent two years on the anniversary date. These options were valued at $153,348 and $61,142 respectively and have a time to expiration of seven years. During the period ended December 31, 2014, 40,000 of the April issuance were cancelled, which is included in a total of $112,573 that has been recorded as stock-based compensation related to the vesting of these stock options.

	On February 17, 2015, the Company issued 314,560 options to a director, employees and a consultant with an exercise price of $0.23, that vest one third immediately and two thirds over the next two anniversary dates with an expiry date of seven years. The grant date fair value of the options was $136,613. During the period ended March 31, 2015, $50,770 has been recorded as stock based compensation related to the vesting of these stock options.															On July 1, 2014, the Company issued a further 945,000 options to employees of the Company, at an exercise price of $0.77 ($0.90 CAD), which vest 90 days after the close of a reverse merger transaction with a concurrent private placement raising a minimum of $6,000,000, see Notes 13 (c) to (f). These options were valued at $719,835 and have a time to expiration of seven years.

	These options granted and revalued during the period ended March 31, 2015 were valued using the Black-Scholes option pricing model with the following key assumptions:															These options were valued using the Black-Scholes option pricing model with the following key assumptions:

			February 17,				July 1,			June 20,			April 11,			Expected life		7 years
			2015				2014			2014			2014			Risk free rate		1.59	%
	Expected life in years			5				4.35			6.32			4.14		Dividend yield		0	%
	Risk free rate			1.59	%			1.59	%		1.59	%		1.59	%	Forfeiture rate		0	%
	Dividend yield			0	%			0	%		0	%		0	%	Volatility (based upon similar public companies)		114	%
	Forfeiture rate			0	%			0	%		0	%		0	%
	Expected volatility			114	%			114	%		114	%		114	%	A summary of the Company’s outstanding and exercisable options is as follows:

	A summary of the Company’s outstanding options is as follows:																	Number of		Weighted Average	Weighted Average
																		options		Exercise Price	Remaining Contract Life
			Number of Options			Weighted-Average Exercise												#		$	(Years)
			Number of Options			Price ($)										Outstanding, March 31, 2012 and 2013		-		-	-
	Outstanding, December 31, 2013			1,310,665			0.19									Granted during the year		416,667		0.52	-
	Exercised			-1,310,665			0.19									Outstanding March 31, 2014		416,667		0.52	0.2
	Issued			3,894,252			0.22									Exercised during the period		-416,667		0.52	-
	Cancelled			-125,824			0.17									Granted during the period		1,238,000		0.73	7
	Outstanding, December 31, 2014			3,768,428			0.22									Cancelled during the period		-40,000		0.52	-
	Cancelled as a result of Acquisition Transaction			-3,768,428			0.22									Outstanding, December 31, 2014		1,198,000		0.74	6.72
	Re-issued as part of Acquisition Transaction			3,768,428			0.22
	Issued			314,560			0.23
	Outstanding, March 31, 2015			4,082,988			0.22

	The following is a summary of stock options outstanding as of March 31, 2015:

	Exercise Price ($)		Number of Options		Expiry Date		Number of Exercisable
	Exercise Price ($)		Number of Options		Expiry Date		Options
	0.165		531,606		11-Apr-21		177,202
	0.23		264,230		20-Jun-21		88,077
	0.23		2,972,592		1-Jul-21		-
	0.23		314,560		17-Feb-22		104,853
			4,082,988				370,132

WARRANTS

WARRANTS	3 Months Ended
WARRANTS	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	9	WARRANTS

	The following is a continuity schedule of the Company's common share purchase warrants:

						Weighted-Average
			Number of Warrants			Exercise Price ($)
	Outstanding and exercisable, December 31, 2014 and 2013			-			-
	Issued			10,823,450			1.35
	Outstanding and exercisable, March 31, 2015			10,823,450			1.35

	The following is a summary of common share purchase warrants outstanding as of March 31, 2015:

		Exercise Price				Number of		Expiry Date
		($)				Warrants		Expiry Date
			1.4		Note 7(vi)		7,735,750	26-Feb-19
			0.8		Note 7(vi)		773,575	26-Feb-19
			1.4		Note 7(viii)		1,212,500	27-Mar-19
			0.8		Note 7(viii)		121,250	27-Mar-19
			1.4		Note 7(ix)		891,250	31-Mar-19
			0.8		Note 7(ix)		89,125	31-Mar-19
							10,823,450

	In 2014 the Company repaid loans of $180,940 plus accrued interest of $12,138 owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares at an exercise price of $0.23 per share for a period of up to two years.

CONTINGENCIES

CONTINGENCIES	3 Months Ended		9 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10	CONTINGENCIES	10	CONTINGENCIES

	From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.		From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.

INCOME_TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11	INCOME TAXES

			9 month periods		Years ended
			ended		Years ended
			December 31, 2014			March 31, 2014		March 31, 2013
			$			$		$
	Components of net loss before income taxes consists of the following:
	U.S.			-		-		-
	Canada			-2,464,747		-1,451,769		-937,059
				-2,464,747		-1,451,769		-937,059

			2014		2014		2013
			$		$		$
	Net loss before recovery of income taxes		-2,464,747		-1,451,769		-937,059

	Statutory rate		26.5	%	26.5	%	26.5	%
	Expected income tax recovery		-653,158		-384,719		-248,321

	Other basis adjustment		-29,109		-6,966		-8,576
	Non-deductible expenses		193,305		148,936		-38,493
	Change in valuation allowance		488,962		242,749		295,390
	Recovery of income taxes		-		-		-

	The components of deferred taxes are as follows:

			2014		2014		2013
			$		$		$
	Deferred tax assets
	Current
			-		403		-
	Valuation allowance		-		-403		-
			-		-		-
	Long-term		$		$		$
	Unrealized tax credits		-		19,591		19,721
	Property and equipment		36,940		23,985		-
	Share issue costs		7,137		6,461		7,228
	SR&ED pool		162,350		-		-
	Other		18,621		-		-
	Net operating losses		812,522		529,889		310,228
	Valuation allowance		-1,037,570		-579,926		-337,177
			-		-		-

RISK_MANAGEMENT

RISK MANAGEMENT	3 Months Ended		9 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	11	RISK MANAGEMENT		12	RISK MANAGEMENT

	The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits.		The Company’s cash balances are maintained in various banks in Canada. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits.

	Interest Rate Risk		Interest Rate Risk

	Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company settled its loans payable and convertible secured promissory note; therefore, it retains minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.		Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company settled its loans payable and convertible secured promissory note; therefore, it retains minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.

	Liquidity Risk		Liquidity Risk

	Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period.		Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period.

	The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.		The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

	Based on management’s assessment of the Company’s cash flow needs, management believes the Company has sufficient cash to sustain operations for an additional 12 -month period.		During the nine months ended December 31, 2014, the Company raised gross proceeds of $2,616,062 from issuances of common shares and raised $228,875 from the exercise of options. The future of the Company is dependent upon its ability to obtain financing and upon achieving profitable operations. Subsequent to period end the Company raised approximately $10,363,000 concurrent with a transaction with Drywave Technologies Inc. (“Drywave”), a U.S public company, see Note 13(c). While the Company has been successful in securing such financing in the past, there is no assurance that it will be able to do so in the future.

			Based on management’s assessment of the Company’s cash flow, and the financing completed subsequent to period end (Note 13(c)), management believes the Company has sufficient cash to sustain operations for an additional 12 month period.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended			9 Months Ended
	Mar. 31, 2015			Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	12	SUBSEQUENT EVENTS			13	SUBSEQUENT EVENTS

		(i)	Subsequent to March 31, 2015, the Company provided a loan to a third party in the amount of $150,000 under normal commercial terms. The loan carries an interest rate of 5% payable semi-yearly, is secured to all assets of the borrower and is repayable in 18 months.		(a)	On January 21, 2015, the Company received a $500,000 loan from a third party which bears interest at 5% per annum and is convertible into common shares of the Company should the transaction to raise at least $6,000,000 be completed (Note 13(c)). On February 26, 2015, the transaction was completed and the loan was converted into common shares.

		(ii)	On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years The Company incurred share issue costs related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years.		(b)	On February 25, 2015, 262,904 common shares of BLC (Note 13(c)) were issued to two former lenders connected with a $241,185 ($250,000 CAD) loan received and repaid during fiscal 2013. In addition, as part of the consideration for the initial loan the CTO and COO had transferred 100,000 shares to the lenders and a further 83,574 additional common shares of BLC (Note 13(c)). The CTO and COO, will be reimbursed for the shares transferred after giving effect to the exchange ratio for BLC (Note 13(c)).

					(c)	On February 26, 2015, the Company (“Bionik Canada”) finalized a Share Exchange Agreement with Bionik Laboratories Corp. (“BLC” formerly known as Drywave Technologies Inc.) whereby Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the outstanding common shares of Bionik Canada (the “Acquisition Transaction”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of common stock of BLC. In addition BLC issued one share of its Special Preferred Voting Stock (the “Special Preferred Share”). Immediately prior to the closing of the Acquisition Transaction, BLC transferred all of the business, properties, assets, operations and liabilities to two former officers and directors of BLC and to a third-party entity such that as of the closing of the Acquisition Transaction there were no assets or liabilities.

				After giving effect to the Acquisition Transaction, BLC commenced operations through Bionik Canada which by virtue of the Acquisition Transaction is now a reporting issuer through BLC’s listing on the OTC Pink marketplace.

				As a result of the shareholders of Bionik Canada having a controlling interest in BLC subsequent to the Acquisition Transaction, for accounting purposes the Acquisition Transaction does not constitute a business combination. The transaction has been accounted for as a recapitalization of BLC with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik.

				Concurrently with the closing of the Acquisition Transaction on February 26, 2015, BLC issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. BLC incurred share issue costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years.

					(d)	Immediately following the Acquisition Transaction and the First Closing, 6,000,000 shares of common stock were held by existing BLC stockholders, 7,735,750 shares of common stock were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of common stock through their ownership of 100% of the Exchangeable Shares which vote alongside the common stock of BLC as a single class through the one issued and outstanding Special Preferred Share.

					(e)	On March 27, 2015, BLC issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. BLC incurred share issue costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years.

					(f)	On March 31, 2015, BLC issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. BLC incurred share issue costs related to the Third Closing of $97,098 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years.

					(g)	On April 21, 2015, BLC sold to accredited investors a fourth closing of the Offering, 3,115,000 Units for gross proceeds of $2,492,000 at the Purchase Price. Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years. BLC incurred share issue costs related to the transaction of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years.

					(h)	On February 17, 2015 BLC issued 100,000 options to a director, employees and a consultant with an exercise price of $0.77 and expiry of seven years. The options vest one third immediately and two thirds over the subsequent two anniversary dates with an expiry of seven years. As a result of the Acquisition Transaction, these options were amended to constitute 314,560 options with an exercise price of $0.23. The fair value of the options, remeasured at the date of the Acquisition Transaction, was $136,613.

					(i)	Subsequent to year end the Company lent a third party $150,000 under normal commercial terms. The loan carries an interest rate of 5% payable semi-yearly and is secured to all assets of the Company. The loan is repayable in 18 months.

					(j)	Upon the close of the Acquisition Transaction, the condition was met on the 945,000 stock options issued to management of the Company, see Note 9, and accordingly the options will vest 90 days from the close of the Acquisition Transaction. As a result of the Acquisition Transaction, these options were amended to constitute 2,972,592 options with an exercise price of $0.23 and will vest on May 27, 2015. The fair value of the options, remeasured at the date of the Acquisition Transaction, was $1,259,487.

				Further, as a result of the Acquisition Transaction, the options issued on April 11, 2014 and June 20, 2014 (Note 9) were amended to constitute 531,606 and 264,230 options of BLC, respectively, with an exercise price of $0.165 and $0.23, respectively. The fair value of the options, remeasured at the date of the Acquisition Transaction, for the 531,606 April issuance and the 264,230 June issuance was $230,930 and $118,957, respectively.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Interim Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements

	These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements for the year ended December 31, 2014. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements

	On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the condensed interim financial statements of adopting ASU 2014-09 will be assessed by management.	“Income Taxes (Topic - 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists” (“ASU 2013-11”) issued in July 2013 provides guidance on how to present an unrecognized tax benefit. The guidance is effective for annual periods beginning after December 15, 2013.

	On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the condensed interim financial statements of adopting ASU 2014-15 will be assessed by management.	On May 28, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016. Early adoption is not permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-09 is being assessed by management.

	Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements.	On August 27, 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the Company’s Financial Statements of adopting ASU 2014-15 is being assessed by management.

		Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation	Foreign Currency Translation

	The Company’s reporting currency is the U.S. dollar. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company is the U.S. dollar, the functional currency of the Company’s wholly-owned subsidiary Bionik Canada and Bionik Acquisition Inc. is the Canadian Dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.	The Company’s functional currency is the Canadian dollar and its reporting currency is the US dollar. The financial statements have been translated into US dollars in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830. All assets and liabilities with Canadian dollars as functional currency are translated at the exchange rate on the balance sheet date, shareholders' equity and share issuances are translated at the historical rates and the statements of operations and cash flows are translated at the average exchange rate for the year. The resulting translation adjustments are reported under comprehensive income as a separate component of shareholders’ equity (deficiency).

	Bionik Canada and Bionik Acquisition Inc.’s assets and liabilities are translated into the U.S. dollar using the exchange rates at each balance sheet date. Revenue and expenses are translated at average rates prevailing during the reporting period. Shareholders’ equity (deficiency) is translated at historical rates. Adjustments resulting from translating the condensed consolidated interim financial statements into the U.S. dollar are recorded as a separate component of accumulated other comprehensive income (loss) in the statement of changes in shareholders’ equity (deficiency).

Use of Estimates, Policy [Policy Text Block]		Use of Estimates

		The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: investment tax credit receivable (see note 3) and the valuation allowance for deferred tax assets.

Property, Plant and Equipment, Policy [Policy Text Block]		Equipment

		Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows:

		Computers and electronics	50% per annum
		Furniture and fixtures	20% per annum
		Tools and parts	20% per annum

Revenue Recognition, Policy [Policy Text Block]		Revenue Recognition

		The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured.

Government Grant and Input Tax Credit Recoveries [Policy Text Block]		Government Grant and Input Tax Credit Recoveries

		The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statements of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when it is certain that such grant and input tax credit recoveries will be received.

Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents

		Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.

Research and Development Expense, Policy [Policy Text Block]		Research and Development

		The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.

Segment Reporting, Policy [Policy Text Block]		Segment Reporting

		ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s does not have any reportable segments. All of its operations and assets are domiciled in Canada.

Income Tax, Policy [Policy Text Block]		Income Taxes

		Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations.

Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value of Financial Instruments

		ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item.

		The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable and accrued liabilities, convertible secured promissory note and due to / from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

		For the loans payable, the Company believes the carrying value of the loans payable approximates fair value as the interest rates are market rates.

		There were no assets or liabilities measured at fair value on a recurring basis as of December 31, 2014 nor March 31, 2014.

Derivatives, Reporting of Derivative Activity [Policy Text Block]		Derivative Financial Instruments

		The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.

		The Company reviews the terms of convertible loans, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants to employees and non-employees in connection with consulting or other services. These options or warrants may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity.

		Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received an immediate charge to income is recognized in order to initially record the derivative instrument liabilities at their fair value.

		The discount from the face value of the convertible debt or equity instruments resulting from allocating some or all of the proceeds to the derivative instruments, together with the stated rate of interest on the instrument, is amortized over the life of the instrument through periodic charges to income, using the effective interest method.

		The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

Earnings Per Share, Policy [Policy Text Block]		Basic and Diluted Loss Per Share

		Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. The dilutive effect of convertible loans is reflected in diluted weighted average number of shares using the if-converted method, when there is a dilutive effect.

		Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents are excluded from the computation of diluted loss per share when their effect is anti-dilutive.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-Lived Assets

		The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.

Recently Adopted Accounting Pronouncements [Policy Text Block]		Recently Adopted Accounting Pronouncements

		“Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements (“ASU 2014-10”) issued in June 2014, ASU 2014-10 eliminated the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders’ equity. The amendments in ASU 2014-10 are effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company adopted ASU 2014-10 for its financial statements and accordingly has removed the inception-to-date information.

		“Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”, (“ASU 2013-2”) issued in February 2013 requires entities to disclose additional information for items reclassified out of accumulated other comprehensive income (“AOCI”). For items reclassified out of AOCI and into net income in their entirety, entities are required to disclose the effect of the reclassification on each affected line item of net income. For AOCI reclassification items that are not reclassified in their entirety into net income, a cross reference to other required U.S. GAAP disclosures is required. This information may be provided either in the notes or parenthetically on the face of the statement that reports net income, provided that all the information is disclosed in a single location. However, an entity is prohibited from providing this information parenthetically on the face of the statement that reports net income, if it has items that are not reclassified in their entirety into net income. The guidance is effective for annual and interim reporting periods beginning after December 15, 2012. The adoption of this standard did not have a material impact on the financial statements of the Company.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property, Plant and Equipment, Depreciation Percentage [Table Text Block]	Equipment is depreciated as follows:

	Computers and electronics	50% per annum
	Furniture and fixtures	20% per annum
	Tools and parts	20% per annum

PREPAID_EXPENSES_AND_OTHER_REC1

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended				9 Months Ended
PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	Mar. 31, 2015				Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]			March 31,	December 31,			December 31,	March 31,
			2015	2014			2014	2014
			$	$			$	$
	Prepaid expenses and sundry receivables		6,242	18,172	Prepaid expenses and sundry receivables		18,172	11,700
	Prepaid insurance		126,771	40,630	Prepaid insurance		40,630	-
	Sales taxes receivable (i)		25,406	22,328	IRAP Grant receivable (i)		-	63,300
			158,419	81,130	Investment tax credit receivable (ii)		-	408,506
					Sales taxes receivable (iii)		22,328	22,281
							81,130	505,787
		(i)	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.
						i)	Industrial Research Assistance Program (“IRAP”) grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as ‘Other Income’ in the statements of operations and comprehensive loss, when received.

						ii)	Investment tax credit receivable is the estimated Scientific Research and Experimental Development (“SR&ED”) claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as ‘Other Income’ in the statements of operations and comprehensive loss.

						iii)	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

EQUIPMENT_Tables

EQUIPMENT (Tables)	3 Months Ended							9 Months Ended
EQUIPMENT (Tables)	Mar. 31, 2015							Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consists of the following as at March 31, 2015 and December 31, 2014.							Equipment consists of the following as at December 31, 2014 and March 31, 2014

		March 31, 2015			December 31, 2014				December 31, 2014			March 31, 2014
		Cost	Accumulated	Net	Cost	Accumulated	Net		Cost	Accumulated	Net	Cost	Accumulated	Net
		Cost	Depreciation	Net	Cost	Depreciation	Net		Cost	Depreciation	Net	Cost	Depreciation	Net
		$	$	$	$	$	$		$	$	$	$	$	$
	Computers and electronics	107,369	33,933	73,436	77,650	27,438	50,212	Computers and electronics	77,650	27,438	50,212	-	-	-
	Furniture and fixtures	23,832	7,689	16,143	24,909	7,325	17,584	Furniture and fixtures	24,909	7,325	17,584	11,194	4,442	6,752
	Tools and parts	12,100	1,050	11,050	11,913	1,787	10,126	Tools and parts	11,913	1,787	10,126	-	-	-
		143,301	42,672	100,629	114,472	36,550	77,922		114,472	36,550	77,922	11,194	4,442	6,752

LOANS_PAYABLE_Tables

LOANS PAYABLE (Tables)	9 Months Ended
LOANS PAYABLE (Tables)	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	As of December 31, 2014 and March 31, 2014, the Company has the following loans:

			December 31, 2014	March 31, 2014
			$	$
	a) Lieberman Family Trust
	The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million). Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014.		-	27,141

	b) Gaston-Dreyfus Remi
	The loan carried interest of 6% per annum and was payable on demand. The loan was secured by a general security agreement on all the assets of the Company.		-	454,729

	c) Parvez Patel/Huda
	The loan was unsecured, carried interest of 2% per annum and was repayable on demand or successful completion of capital raise for $5,694,570 (CAD $6.3 million).		-	100,766

	d) Pope & Co.
	The loan carried interest of 10% per annum and was payable within 90 days of demand or upon successful completion of a capital raise for $2,711,700 (CAD $3 million) by no later than June 30, 2014. Formerly secured by way of partial assignment of the Company’s entitlement to its SR&ED tax credit refund from the Government of Canada for the year ended March 31, 2014.		-	189,510

			-	772,146

		(a)	During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 common shares (Note 8(xii)).

		(b&c)	During the nine month period ended December 31, 2014, the Company repaid the loan of $452,350 ($500,000 CAD) from Gaston-Dreyfus Remi plus accrued interest and the loan of $99,517 ($110,000 CAD) plus accrued interest from Parvez Patel/Huda (both unrelated parties).

		(d)	During the nine month period ended December 31, 2014, the Company repaid loans for $180,940 ($200,000 CAD) plus accrued interest of $12,138 ($13,417 CAD) owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares of BLC (Note 13(c)) at an exercise price of $0.23 per share for a period of up to two years.

SHARE_CAPITAL_Tables

SHARE CAPITAL (Tables)	3 Months Ended
SHARE CAPITAL (Tables)	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]				March 31, 2015					December 31, 2014
				Number of		$			Number of		$
				shares		$			shares		$
	Exchangeable Shares:
	Balance at beginning of period				49,737,096		49,737			36,621,885		36,622
	Shares issued for services		(v)		262,904		263			-		-
	Shares issued under private placement				-		-	(i)		10,792,335		10,792
	Shares issued on conversion and settlement of debt				-		-	(ii)(iii)		1,012,142		1,012
	Shares issued on the exercise of options				-		-	(iv)		1,310,734		1,311
	Balance at end of the period				50,000,000		50,000			49,737,096		49,737
	Common Shares
	Balance at beginning of the period				-		-			-		-
	Shares issued as Acquisition Transaction consideration		(vii)		6,000,000		6,000			-		-
	Shares issued under private placement		(vi)-(ix)		9,839,500		9,840			-		-
	Balance at end of the period				15,839,500		15,840			-		-
	TOTAL COMMON SHARES				65,839,500		65,840			-		-

		(i)	In April, 2014, Bionik Canada completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,590,160. A former director of Bionik Canada assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction.

		(ii)	In May 2014, Bionik Canada issued 436,908 common shares in exchange for the settlement of $138,888 of unsecured debt.

		(iii)	In June, 2014, Bionik Canada issued 575,234 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement.

		(iv)	In June 2014, Bionik Canada issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875.

		(v)	On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 7(vi)), and recorded in stock based compensation on the statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders the Company intends to reimburse the CTO and COO 320,000 shares of common stock; however, these shares have not yet been issued.

		(vi)	Concurrently with the closing of the Acquisition Transaction on February 26, 2015, the Company issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years.

		(vii)	Immediately following the Acquisition Transaction and the First Closing, 6,000,000 shares of common stock were held by existing Drywave stockholders, 7,735,750 shares of common stock were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of common stock through their ownership of 100% of the Exchangeable Shares which vote alongside the common stock of the Company as a single class through the one issued and outstanding Special Preferred Share.

		(viii)	On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years.

		(ix)	On March 31, 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Third Closing of $97,098 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years.

CAPITAL_STOCK_Tables

CAPITAL STOCK (Tables)	9 Months Ended
CAPITAL STOCK (Tables)	Dec. 31, 2014
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]			Number of	Stated
			Common	Value
			Shares	$
	Balance, April 1, 2012 (i)		9,000,000	5
	Issued under private placement (ii)		291,667	170,815
	Issued on settlement of debt relating to prior period services (iii)		200,000	117,192
	Issued under private placement (iv)		895,834	519,420
	Cancellation of common stock (v)		-250,000	-
	Issued under private placement (vi)		437,500	256,016
	Issued under private placement (vii)		383,333	232,546
	Issued under private placement (viii)		516,666	308,183
	Share issue costs		-	-34,583
	Balance, March 31, 2013		11,475,000	1,569,594
	Issued under private placement (ix)		166,667	96,320
	Share issue costs		-	-7,329
	Balance, March 31, 2014		11,641,667	1,658,585
	Issued under private placement (x)		3,430,756	2,616,062
	Issued on conversion and settlement of debt (xi), (xii), (xiii)		321,748	239,746
	Issued on the exercise of options (xiv)		416,667	335,060
	Share issue costs (x)		-	-11,609
	Balance December 31, 2014		15,810,838	4,837,844

		(i)	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2,1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.

		(ii)	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.

		(iii)	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.

		(iv)	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.

		(v)	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.

		(vi)	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.

		(vii)	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.

		(viii)	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.

		(ix)	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.

		(x)	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finder’s fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.

		(xi)	In May 2014, the Company issued 105,555 common shares to a director of the Company in exchange for the settlement of $87,638 ($95,000 CAD) of unsecured debt.

		(xii)	In May 2014, the Company issued 33,333 common shares to the Libermann Family Trust in exchange for the settlement of $27,585 ($30,000 CAD) of unsecured debt.

		(xiii)	In June, 2014, the Company issued 182,860 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 ($131,659 CAD) and was converted at a 20% discount to the $0.68 ($0.90 CAD) April 2014 private placement.

		(xiv)	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	3 Months Ended														9 Months Ended
STOCK OPTIONS (Tables)	Mar. 31, 2015														Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	These options granted and revalued during the period ended March 31, 2015 were valued using the Black-Scholes option pricing model with the following key assumptions:														These options were valued using the Black-Scholes option pricing model with the following key assumptions:

		February 17,				July 1,			June 20,			April 11,			Expected life	7 years
		2015				2014			2014			2014			Risk free rate	1.59	%
	Expected life in years		5				4.35			6.32			4.14		Dividend yield	0	%
	Risk free rate		1.59	%			1.59	%		1.59	%		1.59	%	Forfeiture rate	0	%
	Dividend yield		0	%			0	%		0	%		0	%	Volatility (based upon similar public companies)	114	%
	Forfeiture rate		0	%			0	%		0	%		0	%
	Expected volatility		114	%			114	%		114	%		114	%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s outstanding options is as follows:														A summary of the Company’s outstanding and exercisable options is as follows:

		Number of Options			Weighted-Average Exercise											Number of		Weighted Average	Weighted Average
		Number of Options			Price ($)											options		Exercise Price	Remaining Contract Life
	Outstanding, December 31, 2013		1,310,665			0.19										#		$	(Years)
	Exercised		-1,310,665			0.19									Outstanding, March 31, 2012 and 2013	-		-	-
	Issued		3,894,252			0.22									Granted during the year	416,667		0.52	-
	Cancelled		-125,824			0.17									Outstanding March 31, 2014	416,667		0.52	0.2
	Outstanding, December 31, 2014		3,768,428			0.22									Exercised during the period	-416,667		0.52	-
	Cancelled as a result of Acquisition Transaction		-3,768,428			0.22									Granted during the period	1,238,000		0.73	7
	Re-issued as part of Acquisition Transaction		3,768,428			0.22									Cancelled during the period	-40,000		0.52	-
	Issued		314,560			0.23									Outstanding, December 31, 2014	1,198,000		0.74	6.72
	Outstanding, March 31, 2015		4,082,988			0.22

Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding as of March 31, 2015:

	Exercise Price ($)	Number of Options		Expiry Date		Number of Exercisable
	Exercise Price ($)	Number of Options		Expiry Date		Options
	0.165	531,606		11-Apr-21		177,202
	0.23	264,230		20-Jun-21		88,077
	0.23	2,972,592		1-Jul-21		-
	0.23	314,560		17-Feb-22		104,853
		4,082,988				370,132

WARRANTS_Tables

WARRANTS (Tables)	3 Months Ended
WARRANTS (Tables)	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company's common share purchase warrants:

						Weighted-Average
			Number of Warrants			Exercise Price ($)
	Outstanding and exercisable, December 31, 2014 and 2013			-			-
	Issued			10,823,450			1.35
	Outstanding and exercisable, March 31, 2015			10,823,450			1.35

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following is a summary of common share purchase warrants outstanding as of March 31, 2015:

		Exercise Price				Number of		Expiry Date
		($)				Warrants		Expiry Date
			1.4		Note 7(vi)		7,735,750	26-Feb-19
			0.8		Note 7(vi)		773,575	26-Feb-19
			1.4		Note 7(viii)		1,212,500	27-Mar-19
			0.8		Note 7(viii)		121,250	27-Mar-19
			1.4		Note 7(ix)		891,250	31-Mar-19
			0.8		Note 7(ix)		89,125	31-Mar-19
							10,823,450

	In 2014 the Company repaid loans of $180,940 plus accrued interest of $12,138 owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares at an exercise price of $0.23 per share for a period of up to two years.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	9 Months Ended
INCOME TAXES (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		9 month periods		Years ended
		ended		Years ended
		December 31, 2014			March 31, 2014		March 31, 2013
		$			$		$
	Components of net loss before income taxes consists of the following:
	U.S.		-		-		-
	Canada		-2,464,747		-1,451,769		-937,059
			-2,464,747		-1,451,769		-937,059

		2014		2014		2013
		$		$		$
	Net loss before recovery of income taxes	-2,464,747		-1,451,769		-937,059

	Statutory rate	26.5	%	26.5	%	26.5	%
	Expected income tax recovery	-653,158		-384,719		-248,321

	Other basis adjustment	-29,109		-6,966		-8,576
	Non-deductible expenses	193,305		148,936		-38,493
	Change in valuation allowance	488,962		242,749		295,390
	Recovery of income taxes	-		-		-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The components of deferred taxes are as follows:

		2014		2014		2013
		$		$		$
	Deferred tax assets
	Current
		-		403		-
	Valuation allowance	-		-403		-
		-		-		-
	Long-term	$		$		$
	Unrealized tax credits	-		19,591		19,721
	Property and equipment	36,940		23,985		-
	Share issue costs	7,137		6,461		7,228
	SR&ED pool	162,350		-		-
	Other	18,621		-		-
	Net operating losses	812,522		529,889		310,228
	Valuation allowance	-1,037,570		-579,926		-337,177
		-		-		-

NATURE_OF_OPERATIONS_Details_T

NATURE OF OPERATIONS (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
NATURE OF OPERATIONS (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Working Capital Surplus (Deficit)	$5,783,276	($781,378)	($128,361)		($781,378)
Stockholders' Equity Attributable to Parent	5,883,905	-774,626	-50,439	-710,982	-774,626	471,822	-183,721
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	($1,221,894)	($63,644)	($2,489,137)	($1,429,108)	($1,433,485)	($914,046)
Common Stock, Shares Authorized	150,000,000		200,000,000
Entity Incorporation, Date of Incorporation	8-Jan-10
Common Stock Authorized					Unlimited
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues	50,000,000
Debt Instrument, Convertible, Conversion Ratio	3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	100.00%

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Details)	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2014
Office Equipment [Member]
Percentage Of Depreciated Per Annum	50.00%
Furniture and Fixtures [Member]
Percentage Of Depreciated Per Annum	20.00%
Tools, Dies and Molds [Member]
Percentage Of Depreciated Per Annum	20.00%

PREPAID_EXPENSES_AND_OTHER_REC2

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014		Mar. 31, 2014
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables	$6,242		$18,172		$11,700
Prepaid insurance	126,771		40,630		0
IRAP Grant receivable					63,300	[1]
Investment tax credit receivable					408,506	[2]
Sales taxes receivable	25,406	[3]	22,328	[3]	22,281	[3]
Prepaid Expense and Other Assets	$158,419		$81,130		$505,787

[1]	Industrial Research Assistance Program (bIRAPb) grant receivable is the value of claim receivable from the Government of Canada for recovery of eligible expenditures. The grant proceeds are recognized as bOther Incomeb in the statements of operations and comprehensive loss, when received.
[2]	Investment tax credit receivable is the estimated Scientific Research and Experimental Development (bSR&EDb) claim receivable from the Government of Canada for input tax credits that are granted on qualifying SR&ED expenditures. The recovery, which was received in November 2014, is recognized as bOther Incomeb in the statements of operations and comprehensive loss.
[3]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

EQUIPMENT_Details

EQUIPMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$143,301	$114,472	$11,194
AccumulatedDepreciation	42,672	36,550	4,442
Property, Plant and Equipment, Net	100,629	77,922	6,752
Computers and Electronics [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	107,369	77,650	0
AccumulatedDepreciation	33,933	27,438	0
Property, Plant and Equipment, Net	73,436	50,212	0
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	23,832	24,909	11,194
AccumulatedDepreciation	7,689	7,325	4,442
Property, Plant and Equipment, Net	16,143	17,584	6,752
Tools and Parts [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	12,100	11,913	0
AccumulatedDepreciation	1,050	1,787	0
Property, Plant and Equipment, Net	$11,050	$10,126	$0

EQUIPMENT_Details_Textual

EQUIPMENT (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
EQUIPMENT (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$10,412	$423	$34,036	$1,349	$1,772	$2,330
Payments to Acquire Machinery and Equipment	$38,820	$0	$109,316	$4,557	$0	$8,695

CONVERTIBLE_SECURED_PROMISSORY1

CONVERTIBLE SECURED PROMISSORY NOTE (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended			0 Months Ended	1 Months Ended
	Jun. 10, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012	9-May-14	Feb. 28, 2014
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Description						converted the note plus accrued interest into common shares based on the 20% discount to the $0.81 ($0.90 CAD) per share equity financing		convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing
Debt Instrument, Maturity Date	10-Jun-14					28-Feb-14
Debt Instrument, Convertible, Beneficial Conversion Feature						$27,677
Debt Instrument, Interest Rate Terms								prime plus 1%
Debt Instrument, Basis Spread on Variable Rate		1.00%		1.00%
Interest Expense, Debt		179	17,124	0	0	19,223	0
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			105,262			105,262
Debt Instrument, Interest Rate, Stated Percentage			10.00%			10.00%
Debt Instrument, Description						convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing
Debt Instrument, Maturity Date						28-Feb-14
Debt Instrument, Convertible, Beneficial Conversion Feature				27,677
Debt Instrument, Basis Spread on Variable Rate										1.00%
Debt Instrument, Unamortized Discount			16,238			16,238
Interest Expense, Debt				$27,677	$55,647	$3,939	$7,282
Fair Value Inputs, Discount Rate									20.00%
Debt Instrument, Convertible, Conversion Price									$0.81

LOANS_PAYABLE_Details

LOANS PAYABLE (Details) (USD $)	Dec. 31, 2014		Mar. 31, 2014
Loans Payable, Current	$0		$772,146
Lieberman Family Trust [Member]
Loans Payable, Current	0	[1]	27,141	[1]
Gaston-Dreyfus Remi [Member]
Loans Payable, Current	0	[2]	454,729	[2]
Parvez Patel/Huda [Member]
Loans Payable, Current	0	[2]	100,766	[2]
Pope Co. [Member]
Loans Payable, Current	$0	[3]	$189,510	[3]

[1]	During the nine month period ended December 31, 2014, the loan from Lieberman Family Trust and accrued interest thereon was settled in exchange for 33,333 common shares (Note 8(xii)).
[2]	During the nine month period ended December 31, 2014, the Company repaid the loan of $452,350 ($500,000 CAD) from Gaston-Dreyfus Remi plus accrued interest and the loan of $99,517 ($110,000 CAD) plus accrued interest from Parvez Patel/Huda (both unrelated parties).
[3]	During the nine month period ended December 31, 2014, the Company repaid loans for $180,940 ($200,000 CAD) plus accrued interest of $12,138 ($13,417 CAD) owing to investors introduced by Pope and Co. As part of this transaction the Company will issue to these lenders 349,522 warrants exercisable into common shares of BLC (Note 13(c)) at an exercise price of $0.23 per share for a period of up to two years.

LOANS_PAYABLE_Details_Textual

LOANS PAYABLE (Details Textual) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended
LOANS PAYABLE (Details Textual) (USD $)	Jun. 10, 2013	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2013
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Conversion, Converted Instrument, Shares Issued		33,333
Secured Debt					$241,185
Debt Instrument, Maturity Date	10-Jun-14		28-Feb-14
Stock To Be Issued Upon Conversion of Stock Option		416,666
Share Price		$0.58
Debt Conversion, Original Debt, Amount		58,000
Fair Value of Stock Option Issued		106,185
Debt Conversion, Converted Instrument, Warrants or Options Issued		349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights				$1.35
Warrants Expiration Period		2 years
Accretion of Discount			98,046
Relative Fair Value of Options Issued and Contributed Capital from Shareholders			98,046
Lenders Received Shares From Personal Shareholdings Of Founders		100,000
Loans Payable [Member]
Debt Instrument, Fair Value Disclosure		143,139
Employee Stock Option [Member]
Debt Instrument, Fair Value Disclosure		63,481
Common Stock [Member]
Debt Instrument, Fair Value Disclosure		34,565
Relative Fair Value of Options Issued and Contributed Capital from Shareholders			0
Lieberman Family Trust [Member]
Debt Instrument, Interest Rate, Stated Percentage			10.00%
Debt Instrument, Payment Terms			90 Days
Debt Instrument, Face Amount			2,711,700
Gaston-Dreyfus Remi [Member]
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Debt Instrument, Periodic Payment		452,350
Parvez Patel/Huda [Member]
Debt Instrument, Interest Rate, Stated Percentage		2.00%
Debt Instrument, Face Amount		5,694,570
Debt Instrument, Periodic Payment		99,517
Pope and Co. [Member]
Debt Instrument, Interest Rate, Stated Percentage			10.00%
Debt Instrument, Payment Terms			90 Days
Debt Instrument, Face Amount			2,711,700
Debt Instrument, Periodic Payment, Principal		180,940
Debt Instrument, Periodic Payment, Interest		$12,138
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.23

RELATED_PARTY_TRANSACTIONS_AND1

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) (USD $)	3 Months Ended	9 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Related Party Transaction [Line Items]
Due from Related Parties	$41,480	$44,986	$149,899
Debt Instrument, Basis Spread on Variable Rate	1.00%	1.00%
Repayments of Related Party Debt	37,837	37,837
Related Party Transaction, Amounts of Transaction		85,947
Director [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services		105,555
Accounts Payable, Related Parties		0	48,673
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	7,025
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,490	4,220	16,235
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$9,752	$5,930	$0

SHARE_CAPITAL_Details

SHARE CAPITAL (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
SHARE CAPITAL (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014		Mar. 31, 2013		Dec. 31, 2013
Balance	($50,439)		($774,626)		($183,721)		($710,982)
Shares issued on private placements					117,192
Shares issued under private placement	7,871,601
Shares issued on conversion and settlement of debt (in shares)			33,333
Shares issued on the exercise of options			228,875
Shares issued as Acquisition Transaction consideration	0
Balance	5,883,905		-50,439		471,822		-710,982
Common Stock [Member]
Balance (in shares)	49,737,096		36,621,885		9,000,000	[1]	36,621,885
Balance	49,737		36,622		5	[1]	36,622
Shares issued on private placements (in shares)					200,000	[2]
Shares issued on private placements					117,192	[2]
Shares issued under private placement (in shares)	9,839,500
Shares issued under private placement	9,840
Shares issued on the exercise of options (in shares)			1,310,734	[3]
Shares issued on the exercise of options			1,311	[3]
Shares issued as Acquisition Transaction consideration (in shares)	6,000,000
Shares issued as Acquisition Transaction consideration	6,000
Balance (in shares)	65,839,500		49,737,096		11,475,000		36,621,885
Balance	65,840		49,737		1,569,594		36,622
Exchangable Shares [Member]
Balance (in shares)	49,737,096		36,621,885
Balance	49,737		36,622
Shares issued on private placements (in shares)	262,904	[4]	0
Shares issued on private placements	263	[4]	0
Shares issued under private placement (in shares)	0		10,792,335	[5]
Shares issued under private placement	0		10,792	[5]
Shares issued on conversion and settlement of debt (in shares)	0		1,012,142	[6],[7]
Shares issued on conversion and settlement of debt	0		1,012	[6],[7]
Shares issued on the exercise of options (in shares)	0		1,310,734
Shares issued on the exercise of options	0		1,311
Balance (in shares)	50,000,000		49,737,096
Balance	50,000		49,737
Common Shares [Member]
Balance (in shares)	0		0
Balance	0		0
Shares issued under private placement (in shares)	9,839,500	[10],[11],[8],[9]	0	[10],[11],[8],[9]
Shares issued under private placement	9,840	[10],[11],[8],[9]	0	[10],[11],[8],[9]
Shares issued as Acquisition Transaction consideration (in shares)	6,000,000	[11]	0
Shares issued as Acquisition Transaction consideration	6,000	[11]	0
Balance (in shares)	15,839,500		0
Balance	$15,840		$0

[1]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[2]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[3]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.
[4]	On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 7(vi)), and recorded in stock based compensation on the statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders the Company intends to reimburse the CTO and COO 320,000 shares of common stock; however, these shares have not yet been issued.
[5]	In April, 2014, Bionik Canada completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,590,160. A former director of Bionik Canada assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction.
[6]	In May 2014, Bionik Canada issued 436,908 common shares in exchange for the settlement of $138,888 of unsecured debt.
[7]	In June, 2014, Bionik Canada issued 575,234 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement.
[8]	On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the bSecond Closingb). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years.
[9]	On March 31, 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the bThird Closingb). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the Third Closing of $97,098 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years.
[10]	Concurrently with the closing of the Acquisition Transaction on February 26, 2015, the Company issued 7,735,750 units (the bUnitsb) for gross proceeds of $6,188,600 (the bFirst Closingb) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the bPurchase Priceb) in a private placement offering (the bOfferingb). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years.
[11]	Immediately following the Acquisition Transaction and the First Closing, 6,000,000 shares of common stock were held by existing Drywave stockholders, 7,735,750 shares of common stock were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of common stock through their ownership of 100% of the Exchangeable Shares which vote alongside the common stock of the Company as a single class through the one issued and outstanding Special Preferred Share.

SHARE_CAPITAL_Details_Textual

SHARE CAPITAL (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
SHARE CAPITAL (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Proceeds from issuance of shares, net of issue costs	$6,788,988	$0	$2,604,453	$88,991	$147,837	$1,393,551
Debt Conversion, Converted Instrument, Shares Issued			33,333
Stock Issued During Period, Value, Stock Options Exercised			228,875
Share-based Compensation	371,637	0	112,573	0	0	117,192
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.35
Class of Warrant or Right, Outstanding	10,823,450
Secured Debt				241,185
Unsecured Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued			436,908
Debt Conversion, Converted Instrument, Amount			138,888
Investor [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.23
Exchangable Shares [Member]
Stock Issued During Period, Shares, Other			10,792,335
Shares Issued, Price Per Share			$0.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			1,310,734
Stock Issued During Period, Value, Stock Options Exercised			228,875
Stock Transferred To Lenders	314,560
Stock Reimbursed To Officers	320,000
Share-based Compensation	210,323
Payments of Stock Issuance Costs			11,609
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	50,000,000
Stock Issued During The Period, Value, Issued On Private Placement	262,904
Secured Debt	241,185
First Closing [Member]
Stock Units Issued During Period	7,735,750
Proceeds From Issuance of Stock Units	6,188,600
Stock Units Issued During Period, Purchase Price Per Unit	0.8
Stock Units Description	Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period	4 years
Bridge Loan	500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Payments of Stock Issuance Costs	848,822
Class of Warrant or Right, Outstanding	773,575
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
First Closing [Member] \| Investor [Member]
Stock Issued During Period, Shares, Acquisitions	7,735,750
First Closing [Member] \| Drywave Stockholders [Member]
Stock Issued During Period, Shares, Acquisitions	6,000,000
First Closing [Member] \| Broker warrants [Member]
Warrants Exercisable Period	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Second Closing [Member]
Stock Units Issued During Period	1,212,500
Proceeds From Issuance of Stock Units	970,000
Stock Units Description	Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Payments of Stock Issuance Costs	141,100
Class of Warrant or Right, Outstanding	121,250
Second Closing [Member] \| Broker warrants [Member]
Warrants Exercisable Period	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Third Closing [Member]
Stock Units Issued During Period	891,250
Proceeds From Issuance of Stock Units	713,000
Stock Units Description	Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Payments of Stock Issuance Costs	97,098
Class of Warrant or Right, Outstanding	89,125
Third Closing [Member] \| Broker warrants [Member]
Warrants Exercisable Period	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Convertible Secured Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued			575,234
Debt Conversion, Converted Instrument, Amount			$124,523
Debt Conversion, Converted Instrument, Rate			20.00%

CAPITAL_STOCK_Details

CAPITAL STOCK (Details) (USD $)	9 Months Ended		12 Months Ended
CAPITAL STOCK (Details) (USD $)	Dec. 31, 2014		Mar. 31, 2014		Mar. 31, 2013		Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2013
Class of Stock [Line Items]
Balance	($774,626)		$471,822		($183,721)			$5,883,905	($710,982)
Stock Issued During Period, Value, New Issues	2,616,062		96,320		1,486,980
Stock Issued During Period, Value, Issued for Services					117,192
Stock Issued During Period, Value, Stock Options Exercised	228,875
Financial Services Costs	-11,609	[1]	-7,329		-34,583
Balance	-50,439		-774,626		471,822		-50,439	5,883,905	-710,982
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)	36,621,885		11,475,000		9,000,000	[2]		65,839,500	36,621,885
Balance	36,622		1,569,594		5	[2]		65,840	36,622
Stock Issued During Period Shares New Issues (in shares)	10,792,335		166,667		2,525,000
Stock Issued During Period, Value, New Issues	10,792		96,320		1,486,980
Stock Issued During Period, Shares, Issued for Services (in shares)					200,000	[3]
Stock Issued During Period, Value, Issued for Services					117,192	[3]
Stock Repurchased And Retired During Period Shares (in shares)					-250,000	[4]
Stock Repurchased and Retired During Period, Value					0	[4]
Stock Issued During Period Shares Stock Options Exercised (in shares)	1,310,734	[5]
Stock Issued During Period, Value, Stock Options Exercised	1,311	[5]
Balance (in shares)	49,737,096		36,621,885		11,475,000		49,737,096	65,839,500	36,621,885
Balance	49,737		36,622		1,569,594		49,737	65,840	36,622
Common Stock [Member] \| Debt [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)	321,748	[6],[7],[8]
Stock Issued During Period, Value, New Issues	239,746	[6],[7],[8]
Common Stock [Member] \| Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)					291,667	[9]
Stock Issued During Period, Value, New Issues					170,815	[9]
Common Stock [Member] \| Private Placement One [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)					895,834	[10]
Stock Issued During Period, Value, New Issues					519,420	[10]
Common Stock [Member] \| Private Placement Two [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)					437,500	[11]
Stock Issued During Period, Value, New Issues					256,016	[11]
Common Stock [Member] \| Private Placement Three [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)					383,333	[12]
Stock Issued During Period, Value, New Issues					232,546	[12]
Common Stock [Member] \| Private Placement Four [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)					516,666	[13]
Stock Issued During Period, Value, New Issues					308,183	[13]
Common Stock [Member] \| Private Placement Five [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)			166,667	[14]
Stock Issued During Period, Value, New Issues			96,320	[14]
Common Stock [Member] \| Private Placement Six [Member]
Class of Stock [Line Items]
Stock Issued During Period Shares New Issues (in shares)	3,430,756	[1]					3,182,978
Stock Issued During Period, Value, New Issues	$2,616,062	[1]

[1]	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finderbs fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.
[2]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[3]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[4]	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.
[5]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.
[6]	In May 2014, the Company issued 105,555 common shares to a director of the Company in exchange for the settlement of $87,638 ($95,000 CAD) of unsecured debt.
[7]	In May 2014, the Company issued 33,333 common shares to the Libermann Family Trust in exchange for the settlement of $27,585 ($30,000 CAD) of unsecured debt.
[8]	In June, 2014, the Company issued 182,860 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 ($131,659 CAD) and was converted at a 20% discount to the $0.68 ($0.90 CAD) April 2014 private placement.
[9]	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.
[10]	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.
[11]	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.
[12]	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.
[13]	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.
[14]	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.

CAPITAL_STOCK_Details_Textual

CAPITAL STOCK (Details Textual) (USD $)	9 Months Ended			12 Months Ended
CAPITAL STOCK (Details Textual) (USD $)	Dec. 31, 2014		Dec. 31, 2013	Mar. 31, 2014		Mar. 31, 2013		Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2012
Class of Stock [Line Items]
Stockholders' Equity Attributable to Parent	($50,439)		($710,982)	($774,626)		$471,822		($50,439)	$5,883,905	($183,721)
Stock Issued During Period, Value, New Issues	2,616,062			96,320		1,486,980
Relative Fair Value of Options Issued and Contributed Capital from Shareholders	228,875
Proceeds from Stock Options Exercised	228,875		0	0		0
Stock Issued During Period, Value, Issued for Services						117,192
Director [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	105,555
Common Stock [Member]
Class of Stock [Line Items]
Shares, Outstanding	49,737,096		36,621,885	36,621,885		11,475,000		49,737,096	65,839,500	9,000,000	[1]
Stockholders' Equity Attributable to Parent	49,737		36,622	36,622		1,569,594		49,737	65,840	5	[1]
Stock Issued During Period, Shares, New Issues	10,792,335			166,667		2,525,000
Stock Issued During Period, Value, New Issues	10,792			96,320		1,486,980
Stock Repurchased and Retired During Period, Value						0	[2]
Stock Repurchased and Retired During Period, Shares						250,000	[2]
Relative Fair Value of Options Issued and Contributed Capital from Shareholders	1,311	[3]
Proceeds from Stock Options Exercised								228,875
Stock Issued During Period, Value, Employee Stock Ownership Plan								106,185
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	1,310,734	[3]
Stock Issued During Period, Value, Issued for Services						117,192	[4]
Stock Issued During Period, Shares, Issued for Services						200,000	[4]
Common Stock [Member] \| Debt [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	321,748	[5],[6],[7]
Stock Issued During Period, Value, New Issues	239,746	[5],[6],[7]
Common Stock [Member] \| Debt One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								105,555
Stock Issued During Period, Value, New Issues								87,638
Common Stock [Member] \| Libermann Family Trust [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								33,333
Stock Issued During Period, Value, New Issues								27,585
Common Stock [Member] \| Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						291,667	[8]
Shares Issued, Price Per Share						$0.59
Stock Issued During Period, Value, New Issues						170,815	[8]
Proceeds from Issuance of Private Placement						170,815
Common Stock [Member] \| Private Placement One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						895,834	[9]
Shares Issued, Price Per Share						$0.58
Stock Issued During Period, Value, New Issues						519,420	[9]
Proceeds from Issuance of Private Placement						519,420
Common Stock [Member] \| Private Placement Two [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						437,500	[10]
Shares Issued, Price Per Share						$0.59
Stock Issued During Period, Value, New Issues						256,016	[10]
Proceeds from Issuance of Private Placement						256,016
Common Stock [Member] \| Private Placement Three [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						383,333	[11]
Shares Issued, Price Per Share						$0.61
Stock Issued During Period, Value, New Issues						232,546	[11]
Proceeds from Issuance of Private Placement						232,546
Common Stock [Member] \| Private Placement Four [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues						516,666	[12]
Shares Issued, Price Per Share						$0.60
Stock Issued During Period, Value, New Issues						308,183	[12]
Proceeds from Issuance of Private Placement						308,183
Due From Issuance Of Private Placement						58,846
Common Stock [Member] \| Private Placement Five [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues				166,667	[13]
Shares Issued, Price Per Share				$0.58
Stock Issued During Period, Value, New Issues				96,320	[13]
Proceeds from Issuance of Private Placement				96,320
Common Stock [Member] \| Private Placement Six [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	3,430,756	[14]						3,182,978
Shares Issued, Price Per Share	$0.82							$0.82
Stock Issued During Period, Value, New Issues	2,616,062	[14]
Proceeds from Issuance of Private Placement								2,616,062
Stock Issued During Period Value New Issues To Directors								247,778
Common Stock [Member] \| Private Placement Seven [Member]
Class of Stock [Line Items]
Shares Issued, Price Per Share	$0.68							$0.68
Debt Instrument, Increase, Accrued Interest								124,523
Stock Issued During Period, Shares, Conversion of Units								182,860
Debt Instrument, Interest Rate, Effective Percentage	20.00%							20.00%
Common Stock [Member] \| Principal Owner [Member]
Class of Stock [Line Items]
Shares, Outstanding						7,750,000
Stockholders' Equity Attributable to Parent						2
Common Stock [Member] \| Director [Member]
Class of Stock [Line Items]
Shares, Outstanding						1,000,000
Common Stock [Member] \| Consultant [Member]
Class of Stock [Line Items]
Shares, Outstanding						250,000
Common Stock [Member] \| Director and Consultant [Member]
Class of Stock [Line Items]
Stockholders' Equity Attributable to Parent						$3

[1]	The opening balance consists of 7,750,000 common shares issued to its two founders for a consideration of $2, 1,000,000 commons shares issued to two directors and 250,000 common shares to a consultant for a total of 1,250,000 common shares for consideration of $3.
[2]	In August, 2012, 125,000 common shares each issued to the two founders on March 24, 2011, for a total of 250,000 common shares were cancelled.
[3]	In June 2014, the Company issued 416,667 common shares for the exercise of stock options. The Company received cash of $228,875 ($250,000 CAD). The value of the options, $106,185, was transferred from contributed surplus to share capital on exercise.
[4]	In May, 2012, 200,000 common shares valued at $117,192 were issued for settlement of accounts payable relating to services performed in the prior year, which is included in general and administrative expenses for the year ended March 31, 2013.
[5]	In May 2014, the Company issued 105,555 common shares to a director of the Company in exchange for the settlement of $87,638 ($95,000 CAD) of unsecured debt.
[6]	In May 2014, the Company issued 33,333 common shares to the Libermann Family Trust in exchange for the settlement of $27,585 ($30,000 CAD) of unsecured debt.
[7]	In June, 2014, the Company issued 182,860 common shares on conversion of the convertible secured promissory note (Note 5). The note plus accrued interest totaled $124,523 ($131,659 CAD) and was converted at a 20% discount to the $0.68 ($0.90 CAD) April 2014 private placement.
[8]	In May, 2012, the Company issued through a private placement, 291,667 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $170,815.
[9]	In June, 2012, the Company issued through a private placement, 895,834 common shares at a price of $0.58 (0.60 CAD) per share for aggregate gross proceeds of $519,420.
[10]	In September, 2012, the Company issued through a private placement, 437,500 common shares at a price of $0.59 (0.60 CAD) per share for aggregate gross proceeds of $256,016.
[11]	In December, 2012, the Company issued through a private placement, 383,333 common shares at a price of $0.61 (0.60 CAD) per share for aggregate gross proceeds of $232,546.
[12]	In March 2013, the Company issued through a private placement, 516,666 common shares at a price of $0.60 (0.60 CAD) per share for aggregate gross proceeds of $308,183. $58,846 of the proceeds were not received as at March 31, 2013 and accordingly are presented as subscriptions receivable on the balance sheet.
[13]	In June, 2013, the Company issued through a private placement, 166,667 common shares at a price of $0.58 ($0.60 CAD) per share for aggregate gross proceeds of $96,320.
[14]	In April, 2014, the Company completed a private placement issuing 3,182,978 common shares at a price of $0.82 ($0.90 CAD) per share for gross proceeds of $2,616,062 ($2,864,680 CAD). A former director of the Company assisted in securing a significant portion of this financing. As a result the Company issued 247,778 common shares as a finderbs fee to this director. The Company also incurred $11,609 in share issue costs related to the transaction.

STOCK_OPTIONS_Details

STOCK OPTIONS (Details)	9 Months Ended	3 Months Ended
STOCK OPTIONS (Details)	Dec. 31, 2014	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	7 years
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
February 17, 2015 [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years		5 years
Risk free rate		1.59%
Dividend yield		0.00%
Forfeiture rate		0.00%
Expected volatility		114.00%
July 1, 2014 [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years		4 years 4 months 6 days
Risk free rate		1.59%
Dividend yield		0.00%
Forfeiture rate		0.00%
Expected volatility		114.00%
June 20, 2014 [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years		6 years 3 months 25 days
Risk free rate		1.59%
Dividend yield		0.00%
Forfeiture rate		0.00%
Expected volatility		114.00%
April 11, 2014 [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years		4 years 1 month 20 days
Risk free rate		1.59%
Dividend yield		0.00%
Forfeiture rate		0.00%
Expected volatility		114.00%

STOCK_OPTIONS_Details_1

STOCK OPTIONS (Details 1) (Employee Stock Option [Member], USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares)	3,768,428	416,667	1,310,665	0
Number Options, Exercised (in shares)		-416,667	-1,310,665
Number of Options, Issued (in shares)	314,560	1,238,000	3,894,252	416,667
Number of Options, Cancelled (in shares)	-3,768,428	-40,000	-125,824
Number of Options, Re-issued as part of Acquisition Transaction (in shares)	3,768,428
Number of Options, Outstanding, Ending Balance (in shares)	4,082,988	3,768,428	3,768,428	416,667	0
Weighted-Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)	$0.22	$0.52	$0.19	$0
Weighted-Average Exercise Price, Exercised (in dollars per share)		$0.52	$0.19
Weighted-Average Exercise Price, Issued (in dollars per share)	$0.23	$0.73	$0.22	$0.52
Weighted-Average Exercise Price, Cancelled (in dollars per share)	$0.22	$0.52	$0.17
Weighted-Average Exercise Price, Re-issued as part of Acquisition Transaction (in dollars per share)	$0.22
Weighted-Average Exercise Price, Outstanding, Ending Balance (in dollars per share)	$0.22	$0.22	$0.22	$0.52	$0
Weighted Average Remaining Contract Life, Outstanding		6 years 8 months 19 days		2 months 12 days	0 years
Weighted Average Remaining Contract Life, Exercised during the period		0 years
Weighted Average Remaining Contract Life, Granted during the period		7 years		0 years
Weighted Average Remaining Contract Life, Cancelled during the period		0 years

STOCK_OPTIONS_Details_2

STOCK OPTIONS (Details 2) (Employee Stock Option [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$0.22	$0.22	$0.52	$0.19	$0
Number of Options	4,082,988	3,768,428	416,667	1,310,665	0
Number of Exercisable Options	370,132
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$0.17
Number of Options	531,606
Expiry Date	11-Apr-21
Number of Exercisable Options	177,202
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$0.23
Number of Options	264,230
Expiry Date	20-Jun-21
Number of Exercisable Options	88,077
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$0.23
Number of Options	2,972,592
Expiry Date	1-Jul-21
Number of Exercisable Options	0
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$0.23
Number of Options	314,560
Expiry Date	17-Feb-22
Number of Exercisable Options	104,853

STOCK_OPTIONS_Details_Textual

STOCK OPTIONS (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
STOCK OPTIONS (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	15.00%
Allocated Share-based Compensation Expense	$371,637	$0	$112,573	$0	$0	$117,192
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			1,259,487
Percentage of Option Granted			8.00%
Stock Issued During Period, Value, Share-based Compensation, Gross	371,637
Minimum Offering Amount			6,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			125,824
Employee Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			416,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price			$0.52
Stock Issued During Period, Value, Share-based Compensation, Gross			106,185
Employee Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			209,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price			$0.52
Stock Issued During Period, Value, Share-based Compensation, Gross			153,348
Stock Issued During Period, Shares, Share-based Compensation, Forfeited			40,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited			112,573
Employee Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price			$0.77
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Addition			945,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited			719,835
April issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			531,606
Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value			230,930
Allocated Share-based Compensation Expense	73,860
June issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number			264,230
Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value			118,957
Allocated Share-based Compensation Expense	36,684
Employees and Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			84,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price			$0.77
Stock Issued During Period, Value, Share-based Compensation, Gross			61,142
Employees and Consultant [Member] \| April issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			657,430
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$0.17
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1			7 years
Employees and Consultant [Member] \| June issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			264,230
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$0.23
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1			7 years
Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			2,972,592
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$0.23
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1			7 years
Director and Employees and Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	314,560
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$0.23
Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1	7 years
Allocated Share-based Compensation Expense	50,770
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$136,613

WARRANTS_Details

WARRANTS (Details) (USD $)	3 Months Ended
WARRANTS (Details) (USD $)	Mar. 31, 2015
Number of Warrants, Outstanding and exercisable, December 31, 2014 and 2013	0
Number of Warrants, Issued	10,823,450
Number of Warrants, Outstanding and exercisable, March 31, 2015	10,823,450
Weighted-Average Exercise Price, Outstanding and exercisable, December 31, 2014 and 2013	$0
Weighted-Average Exercise Price, Issued	$1.35
Weighted-Average Exercise Price, Outstanding and exercisable, March 31, 2015	$1.35

WARRANTS_Details_1

WARRANTS (Details 1) (USD $)	3 Months Ended
WARRANTS (Details 1) (USD $)	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.35
Class of Warrant or Right, Outstanding	10,823,450
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Class of Warrant or Right, Outstanding	7,735,750
Class Of Warrant Or Right Expiry Date	26-Feb-19
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Class of Warrant or Right, Outstanding	773,575
Class Of Warrant Or Right Expiry Date	26-Feb-19
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Class of Warrant or Right, Outstanding	1,212,500
Class Of Warrant Or Right Expiry Date	27-Mar-19
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Class of Warrant or Right, Outstanding	121,250
Class Of Warrant Or Right Expiry Date	27-Mar-19
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$1.40
Class of Warrant or Right, Outstanding	891,250
Class Of Warrant Or Right Expiry Date	31-Mar-19
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.80
Class of Warrant or Right, Outstanding	89,125
Class Of Warrant Or Right Expiry Date	31-Mar-19

WARRANTS_Details_Textual

WARRANTS (Details Textual) (USD $)	9 Months Ended
WARRANTS (Details Textual) (USD $)	Dec. 31, 2014	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued	349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights		$1.35
Warrants Expiration Period	2 years
Investor [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt	180,940
Debt Conversion, Converted Instrument, Warrants or Options Issued	349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.23
Warrants Expiration Period	2 years
Investor [Member] \| Accrued Liabilities [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt	12,138

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	9 Months Ended	12 Months Ended
INCOME TAXES (Details) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
U.S.	$0	$0	$0
Canada	-2,464,747	-1,451,769	-937,059
Net loss before income taxes	($2,464,747)	($1,451,769)	($937,059)

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	9 Months Ended	12 Months Ended
INCOME TAXES (Details 1) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Net loss before recovery of income taxes	($2,464,747)	($1,451,769)	($937,059)
Statutory rate	26.50%	26.50%	26.50%
Expected income tax recovery	-653,158	-384,719	-248,321
Other basis adjustment	-29,109	-6,966	-8,576
Non-deductible expenses	193,305	148,936	-38,493
Change in valuation allowance	488,962	242,749	295,390
Recovery of income taxes	$0	$0	$0

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
Deferred tax assets Current	$0	$403	$0
Valuation allowance	0	-403	0
Deferred Tax Assets, Net of Valuation Allowance, Current	0	0	0
Long-term Unrealized tax credits	0	19,591	19,721
Property and equipment	36,940	23,985	0
Share issue costs	7,137	6,461	7,228
SR&ED pool	162,350	0	0
Other	18,621	0	0
Net operating losses	812,522	529,889	310,228
Valuation allowance	-1,037,570	-579,926	-337,177
Deferred Tax Liabilities, Net	$0	$0	$0

RISK_MANAGEMENT_Details_Textua

RISK MANAGEMENT (Details Textual)	9 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015	Dec. 31, 2014
	USD ($)	USD ($)	USD ($)	USD ($)	CAD	CAD
Concentration Risk [Line Items]
Cash, FDIC Insured Amount					100,000	100,000
Stock Issued During Period, Value, New Issues	2,616,062		96,320	1,486,980
Proceeds from Stock Options Exercised	$228,875	$0	$0	$0

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member], USD $)	1 Months Ended
	5-May-15	Apr. 21, 2015
Term Loan [Member]
Subsequent Event [Line Items]
Loans and Leases Receivable, Related Parties	$150,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayment Terms	repayable in 18 months
Fourth Closing [Member]
Subsequent Event [Line Items]
Payments of Stock Issuance Costs		338,960
Stock Units Issued During Period		3,115,000
Proceeds From Issuance of Stock Units		$2,492,000
Stock Units Description		Each Unit consisted of one common share of BLC, and a warrant to purchase one common share of BLC at an exercise price of $1.40 per share exercisable for 4 years.
Fourth Closing [Member] \| Broker warrants [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.80
Warrant Exercisable Period		4 years
Class of Warrant or Right, Outstanding		311,500